Nkarta – Allogeneic CAR Natural Killer (NK) Cell Therapy

Paul Hastings, CEO of Nkarta Therapeutics discusses results from their NKX101 study, an allogeneic CAR Natural Killer (NK) cell therapy, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS).

Paul is the President and Chief Executive Officer of Nkarta, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer. After beginning his career in sales and marketing at Hoffman-LaRoche, he has led more than a dozen biopharma companies as CEO, President or Director. He currently serves as Vice Chair and member of the Executive Committee of BIO.

Liked it? Take a second to support healthprofessionalradio on Patreon!


Leave a Reply

You must be logged in to post a comment.